- Home
- EXK vs OCS Comparison
EXK vs OCS Comparison
Compare EXK & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- OCS
- Stock Information
- Founded
- EXK 1981
- OCS 2003
- Country
- EXK Canada
- OCS Switzerland
- Employees
- EXK N/A
- OCS N/A
- Industry
- EXK Precious Metals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- OCS Health Care
- Exchange
- EXK Nasdaq
- OCS Nasdaq
- Market Cap
- EXK 949.5M
- OCS 1.0B
- IPO Year
- EXK N/A
- OCS N/A
- Fundamental
- Price
- EXK $4.69
- OCS $19.28
- Analyst Decision
- EXK Strong Buy
- OCS Strong Buy
- Analyst Count
- EXK 3
- OCS 3
- Target Price
- EXK $6.83
- OCS $35.33
- AVG Volume (30 Days)
- EXK 18.0M
- OCS 30.1K
- Earning Date
- EXK 07-31-2025
- OCS 05-08-2025
- Dividend Yield
- EXK N/A
- OCS N/A
- EPS Growth
- EXK N/A
- OCS N/A
- EPS
- EXK N/A
- OCS N/A
- Revenue
- EXK $217,412,000.00
- OCS $847,333.00
- Revenue This Year
- EXK $99.18
- OCS $18.70
- Revenue Next Year
- EXK $49.21
- OCS $1,059.78
- P/E Ratio
- EXK N/A
- OCS N/A
- Revenue Growth
- EXK 1.72
- OCS N/A
- 52 Week Low
- EXK $2.46
- OCS $10.79
- 52 Week High
- EXK $5.67
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- EXK 61.77
- OCS 51.81
- Support Level
- EXK $4.31
- OCS $18.64
- Resistance Level
- EXK $5.07
- OCS $19.73
- Average True Range (ATR)
- EXK 0.27
- OCS 0.58
- MACD
- EXK 0.03
- OCS -0.07
- Stochastic Oscillator
- EXK 69.57
- OCS 36.57
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.